PM⁴Onco

Personalized medicine (PM4Onco) aims to help identify targeted treatments for people affected by rare and/or difficult-to-treat cancers. To this end, researchers need as much data as possible on which to base their decisions on individual therapies. In Germany, this data is available in different locations, in different forms and from different sources. Increasing digitalization now offers the opportunity to harmonize all this data from a wide variety of sources. This newly acquired wealth of data will enable better, more accurate and therefore more promising treatment approaches to be developed. A total of 25 partners from across Germany have joined forces in "Personalized Medicine for Oncology" (PM⁴Onco), including 22 university medical centers from ten federal states, to work together on a viable and, above all, usable solution. In addition, the project is collaborating with the Luxembourg Institute of Health to explore potential opportunities for Europe-wide use. PM⁴Onco aims to create a permanent infrastructure for the secure use and exchange of data from clinical and biomedical research. The precise analysis of genetic changes in tumors at the respective stage of the disease is crucial so that molecular tumor boards in oncology centers of excellence can recommend the most appropriate individual therapy.